4P004 is a GLP-1 analog, tailored for intra-articular use in knee osteoarthritis ... In addition, the study aims to assess ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...

A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 among U.S. adults without diabetes. The research, published April 1 in the ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate ...

We recently published a list of Was Jim Cramer Right About These 13 Stocks? In this article, we are going to take a look at where PepsiCo Inc. (NASDAQ:PEP) stands against other stocks that Jim ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

Global pharmaceutical companies entering the obesity drug market, currently dominated by Denmark's Novo Nordisk and the United States' Eli Lilly, are introducing new strategies to target market entry.